PDCD1 and hepatocellular carcinoma: A multicenter, phase III, randomized, double-blinder study (NCT03605706) is evaluating the combination of camrelizumab (anti-PD-1 mAb) with FOLFOX4 regimen (fluorouracil+calcium folinate+oxaliplatin) compared with placebo plus FOLFOX4 in patients with advanced HCC who have never received prior systemic treatment.